Standard ADT (androgen deprivation therapy) clinical trials

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

This study compares two ways of giving a prostate cancer drug, Docetaxel, along with standard treatments Darolutamide and ADT. It aims to find out which schedule causes fewer serious side effects in men with advanced prostate cancer.